Trade Royalty Pharma plc - RPRX CFD

Royalty Pharma plc Company profile

About Royalty Pharma plc

Royalty Pharma plc is engaged in investing in late stage biopharmaceutical products. The Company invests in academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. The Company’s portfolio of pharmaceutical investment includes investments in commercial products and development-stage product candidates. Its portfolio investments include AbbVie and J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’ Promacta, Vertex’s Kalydeco, Orkambi, Symdeko, Trikafta and OXLUMO.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Royalty Pharma plc revenues increased 8% to $2.29B. Net income applicable to common stockholders increased 25% to $619.7M. Revenues reflect Income from financial royalty assets increase of 5% to $2.07B, Other royalty income increase from $19M to $53.1M, Revenue from intangible royalty assets increase of 19% to $171.2M. Net income benefited from Other operating expenses decrease from $65.1M (expense) to $0K.